354,188 Shares in Option Care Health, Inc. $OPCH Acquired by Cubist Systematic Strategies LLC

Key Points

• Cubist Systematic Strategies LLC has taken a new position in Option Care Health, investing approximately $12.38 million for 354,188 shares, representing about 0.22% ownership of the company.
• Several other institutional investors have also increased their stakes in Option Care Health, with 98.05% of the stock owned by hedge funds and institutions.
• Analysts have a positive outlook on Option Care Health, with an average rating of "Moderate Buy" and a target price increase to $38.00 according to JMP Securities and Barrington Research.

Cubist Systematic Strategies LLC acquired a new position in Option Care Health, Inc. (NASDAQ:OPCH - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 354,188 shares of the company's stock, valued at approximately $12,379,000. Cubist Systematic Strategies LLC owned approximately 0.22% of Option Care Health as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Option Care Health by 1,492.9% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 892 shares of the company's stock worth $31,000 after purchasing an additional 836 shares during the period. Brooklyn Investment Group boosted its stake in shares of Option Care Health by 186.6% during the 1st quarter. Brooklyn Investment Group now owns 1,198 shares of the company's stock worth $42,000 after purchasing an additional 780 shares during the period. Public Employees Retirement System of Ohio boosted its stake in shares of Option Care Health by 21.6% during the 4th quarter. Public Employees Retirement System of Ohio now owns 1,870 shares of the company's stock worth $43,000 after purchasing an additional 332 shares during the period. Bessemer Group Inc. boosted its stake in shares of Option Care Health by 62.3% during the 1st quarter. Bessemer Group Inc. now owns 1,560 shares of the company's stock worth $54,000 after purchasing an additional 599 shares during the period. Finally, Wealthquest Corp purchased a new position in shares of Option Care Health during the 1st quarter worth about $66,000. 98.05% of the stock is owned by hedge funds and other institutional investors.

Option Care Health Stock Up 1.7%

Shares of NASDAQ:OPCH traded up $0.49 during trading hours on Wednesday, hitting $28.93. The company's stock had a trading volume of 1,900,211 shares, compared to its average volume of 1,717,588. Option Care Health, Inc. has a 52 week low of $21.39 and a 52 week high of $35.53. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.52 and a quick ratio of 1.00. The company has a market capitalization of $4.70 billion, a price-to-earnings ratio of 23.14, a P/E/G ratio of 1.75 and a beta of 0.82. The firm's fifty day moving average price is $29.42 and its 200 day moving average price is $31.59.

Option Care Health (NASDAQ:OPCH - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.40 by $0.01. Option Care Health had a net margin of 3.93% and a return on equity of 17.53%. The business had revenue of $1.42 billion during the quarter, compared to analyst estimates of $1.35 billion. During the same quarter in the previous year, the business posted $0.30 EPS. The company's quarterly revenue was up 15.4% compared to the same quarter last year. Option Care Health has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, research analysts expect that Option Care Health, Inc. will post 1.22 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on OPCH shares. Barrington Research reaffirmed an "outperform" rating and set a $38.00 price target on shares of Option Care Health in a research note on Thursday, July 10th. Citigroup reaffirmed an "outperform" rating on shares of Option Care Health in a research note on Thursday, July 31st. Finally, JMP Securities lifted their price target on shares of Option Care Health from $36.00 to $38.00 and gave the stock a "market outperform" rating in a research note on Thursday, July 31st. Eight equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $35.75.

Insider Activity

In other Option Care Health news, Director Timothy P. Sullivan purchased 20,000 shares of Option Care Health stock in a transaction dated Thursday, August 21st. The stock was acquired at an average price of $27.51 per share, for a total transaction of $550,200.00. Following the acquisition, the director owned 49,229 shares in the company, valued at $1,354,289.79. This trade represents a 68.43% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Harry M. Jansen Kraemer, Jr. acquired 36,000 shares of Option Care Health stock in a transaction that occurred on Wednesday, August 20th. The shares were purchased at an average price of $27.15 per share, with a total value of $977,400.00. Following the purchase, the director owned 375,390 shares in the company, valued at $10,191,838.50. This represents a 10.61% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 0.64% of the company's stock.

Option Care Health Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.